REGISTERED COMPANY NUMBER: 06996068 (England and Wales) REGISTERED CHARITY NUMBER: 1132984
REPORT OF THE TRUSTEES AND UNAUDITED FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST AUGUST 2020
FOR
THE INTERNATIONAL CML FOUNDATION
Gibbons Mannington & Phipps LLP Chartered Accountants 20 Eversley Road Bexhill-on-Sea East Sussex TN40 1HE
THE INTERNATIONAL CML FOUNDATION
CONTENTS OF THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST AUGUST 2020
| Page | Page | |
|---|---|---|
| Report of the Trustees | 1 to | 5 |
| Independent Examiner's Report | 6 | |
| Statement of Financial Activities | 7 | |
| Balance Sheet | 8 | |
| Notes to the Financial Statements | 9 to | 17 |
THE INTERNATIONAL CML FOUNDATION (REGISTERED NUMBER: 06996068)
REPORT OF THE TRUSTEES FOR THE YEAR ENDED 31ST AUGUST 2020
The trustees who are also directors of the charity for the purposes of the Companies Act 2006, present their report with the financial statements of the charity for the year ended 31st August 2020. The trustees have adopted the provisions of Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019).
OBJECTIVES AND ACTIVITIES
Objectives and aims
The object of the Foundation is the advancement of health by the improvement of the treatment in all parts of the world of chronic myeloid leukaemia and related diseases (together "CML") and for the purpose of carrying out those general objects, the primary objects of the Foundation are in particular:-
(i) to improve clinical practice and disease monitoring in the treatment of CML
(ii) to support, encourage and promote research into the causes, prevention, study and treatment of CML
(iii) to promote and support the education of and disseminate knowledge amongst clinicians, scientists, health professionals and patients in matters concerning CML (iv) to promote, foster and co-ordinate collaboration that is particularly (but not exclusively) international and is not only in the areas and activities of clinical practice disease monitoring and research into CML but also in any area or activity which is or may be conducive to the acceleration of the control and/or cure of CML
(v) to promote, set up, establish and support and share and exchange knowledge with other organisations whose objects are similar to these general or primary objects
(vi) to assist or promote any other charitable purposes which are related to these general and primary objects.
Significant activities
In furtherance of the objects, the Foundation has the following powers:-
(i) to promote or carry out research
(ii) to provide advice
(iii) to give and exchange information and advice and promote learning, study and research
(iv) to commission, publish, distribute and contribute to papers, books, periodicals, reports, leaflets, posters and other publications of any description
(v) to hold, attend and sponsor conferences, meetings, lectures, exhibitions and discussions
(vi) to raise funds and to apply for and solicit grants from pharmaceutical companies anywhere in the world.
Public benefit
The Trustees have considered their duty to have due regard to public benefit guidance published by the Commission and in their opinion, the foregoing report on the achievements and performance demonstrates that they have complied therewith.
Page 1
THE INTERNATIONAL CML FOUNDATION (REGISTERED NUMBER: 06996068)
REPORT OF THE TRUSTEES FOR THE YEAR ENDED 31ST AUGUST 2020
ACHIEVEMENT AND PERFORMANCE
Charitable activities
The 2019/2020-year for the iCMLf can clearly be separated into pre and post pandemic activities. September to December 2019 saw the conclusion of the fundraising activity where 26 members of the iCMLf climbed Mount Kilimanjaro and raised over $300,000 for the iCMLf cure programs. While in Africa we hosted the first iCMLf education symposium on the continent, which was closely followed by the iCMLf Forum for physicians from emerging regions in the USA. 10 physicians finalized their preceptorships and 20 more were accepted into the 2020 program.
In February 2020 it become clear that the pandemic was going to fundamentally change the activities, programs and funding of the Foundation. We halted all travel for the preceptors and the program is on hiatus for the foreseeable future.
Given lack of knowledge and concern for patient's vulnerability, the experts treating CML started to share experiences and ideas. This international collaboration began organically and it quickly became clear that the iCMLf was ideally positioned to coordinate this effort. As case collection expanded and formalised, we formed the iCMLf CANDID (Cml AND covID) study. The primary aim of this study is to collect emerging clinical data on CML patients infected with the SARS-CoV-2 virus as rapidly as possible. To date 202 cases have been collected and an abstract accepted for presentation at the American Society of Hematology meeting in December 2020.
As information changed and the pandemic worsened the Foundation initiated key activities to provide guidance and reassurance to both physicians and their CML patients alike. The online COVID-19 hub hosts expert statements, frequently asked questions, relevant clinical papers and other reliable resources. Launched in April 2020 the Hub has had 28,000 views to the 31st August.
The iCMLf hosted live webinars with CML experts, on how to manage patients with CML during the COVID-19 pandemic. Commencing in May 2020, by 31st August 5 webinars had 400 participants and 1,300 views once available online.
Online Education Services
WWW.CML-FOUNDATION.ORG
The iCMLf website has always been one of the key worldwide educational online resources for CML. In 2019/20 there were more than 25,000 visitors and 63,000 page visits. A 54% increase on 2018/2019.
Visitors were from 166 different countries and 71 % of these are low and middle-income countries.
Most visited pages focused on COVID-19 this year with the 3 highest viewed pages being; 1) Advice for people with CML and COVID-19, 2) Case Discussion Forum, 3) COVID-19 Hub.
Virtual Education Programme
19 new education modules were added in 2019/20. There were 4,890 presentations viewed in the year. A 385 increase on 2018/19.
Clinical Case Discussion Forum
This saw more than 8,340 case views during 2019/20. A 15% increase on 2018/19
COVID-19 Hub - New program April to August 2020
Advice and information for people with CML and COVID-19 with 28,000 views to date.
iCMLf Conversations - New program May to August 2020
The iCMLf hosted 5 live webinars with CML experts. Over 400 participants and more than 1,300 views on-demand to date.
Page 2
THE INTERNATIONAL CML FOUNDATION (REGISTERED NUMBER: 06996068)
REPORT OF THE TRUSTEES FOR THE YEAR ENDED 31ST AUGUST 2020
Preceptorships
The iCMLf Clinical Preceptorship Program continues to improve the knowledge and skills of physicians treating CML in emerging economic regions through individually tailored observerships. During their 3-4 week intensive program, participants are involved in outpatient clinics, haematology ward rounds, seminars, discussion forums and laboratory work to arm them with a practical understanding of the most up-to-date protocols and guidelines to treat CML. One of the most valued benefits continues to be the close contacts and networks established during their time at the centre which continue to support their needs even after they have returned home.
From 1st September 2019 to 31st December 2019 10 physicians from emerging regions took part in the program. In January 2020 a further 20 preceptors were accepted into the program with 11 confirmed dates and 2 incurring travel costs.
Fundraising activities
The fundraising activity is a large component of the Chief Executive's travel to the scientific meetings as these are where future funding with potential donors is discussed.
In 2019/2020 our major public fundraising activity was preparation for the iCMLf climb for a cure in October 2019. A team of 26 people climbed Mount Kilimanjaro and raised $305,000 in total (2018-2020)
Funds raised in 2019 from the annual John Goldman Fun Run also supported the iCMLf Climb for a Cure.
FINANCIAL REVIEW
Financial position
The financial position of the International CML Foundation remains solid.
Principal funding sources
The iCMLf works closely with industry and community partners to secure unrestricted grants and sponsorship for our programs and activities. The iCMLf requests donations through the iCMLf website. In 2019/2020 funds were raised through the fundraising adventure the iCMLf Climb for a Cure and on the annual John Goldman Fun Run.
Reserves policy
The reserves at the year end were £383,014 (2019 - £409,720). It is the policy of the Trustees to maintain sufficient reserves to ensure the day to day running of the Foundation. The level of reserves and current financial commitments are reviewed regularly at Trustees' meetings.The Foundation plans to hold a minimum of £150,000 as reserve funding. This is the amount for the foundation to operate without further income/outgoings for one year.
FUTURE PLANS
While maintaining the expert best practice and education initiatives of the Foundation, we aim to harness global network of the iCMLf to enhance research into potential cures for CML. The iCMLf Genomics Alliance will access the wealth of genomic information that is generated in local CML research projects by facilitating data assimilation and samples exchanges through an international data collection platform. Combining many data sets and facilitating global collaborative studies will enable us to develop a baseline predictor of adverse outcomes.
The iCMLf TFR Alliance looks to define biomarkers for treatment discontinuation and a functional cure of CML.
The CML and COVID-19 retrospective case analysis will provide data for physicians to base treatment decisions on as the pandemic continues and vaccines become available.
STRUCTURE, GOVERNANCE AND MANAGEMENT Governing document
The charity is controlled by its governing document, a deed of trust, and constitutes a limited company, limited by guarantee, as defined by the Companies Act 2006.
Page 3
THE INTERNATIONAL CML FOUNDATION (REGISTERED NUMBER: 06996068)
REPORT OF THE TRUSTEES FOR THE YEAR ENDED 31ST AUGUST 2020
STRUCTURE, GOVERNANCE AND MANAGEMENT
Recruitment and appointment of new trustees
The power of appointing new or additional Trustees is vested in the existing Trustees. Prior to appointment, new Trustees would be introduced to the workings of the Foundation and advised of their responsibilities.
Organisational structure
The chief executive reports to the ten iCMLf Directors, specifically the iCMLf Chairman.
The operational team; Communications Director, Digital Media Officer, and ERSAP Program Coordinator, report to the chief executive.
Strategic direction, financial review and budget approval are set at an annual iCMLf directors meeting in September each year. Further directors planning and discussion meetings are held quarterly.
Strategic planning is assisted with an annual advisors meeting. This includes the thirteen physicians, scientific and patient advisors and members from the 36 countries with iCMLf National Representatives.
The operational team meets every 6-8 weeks. The editor and chief executive meet biweekly and the program coordinator and chief executive meet weekly for business planning. The chief executive and iCMLf Chairman meet monthly.
Decisions are escalated from the operational team to the chief executive, iCMLf Chairman and iCMLf Board of Directors according to scale and impact.
REFERENCE AND ADMINISTRATIVE DETAILS
Registered Company number
06996068 (England and Wales)
Registered Charity number
1132984
Registered office
20 Eversley Road Bexhill-on-Sea East Sussex TN40 1HE
Trustees
Professor T P Hughes Professor Professor M Baccarani Professor Professor J Cortes Professor Professor B Druker Professor Professor A Hochhaus Professor Professor J Radich Professor Professor C Schiffer Professor Professor J F Apperley DM FRCP/Path Professor Professor M Mauro Professor Professor G Saglio Professor
Company Secretary
Ms N C Evans
Page 4
THE INTERNATIONAL CML FOUNDATION (REGISTERED NUMBER: 06996068)
REPORT OF THE TRUSTEES FOR THE YEAR ENDED 31ST AUGUST 2020
REFERENCE AND ADMINISTRATIVE DETAILS Independent Examiner R Appleyard FCA ICAEW Gibbons Mannington & Phipps LLP Chartered Accountants 20 Eversley Road Bexhill-on-Sea East Sussex TN40 1HE
Bankers
HSBC Bank, 152 Portobello Road, London, W11 2EA
This report has been prepared in accordance with the special provisions of Part 15 of the Companies Act 2006 relating to small companies.
Approved by order of the board of trustees on 9th June 2021 and signed on its behalf by:
Professor T P Hughes - Trustee
Page 5
INDEPENDENT EXAMINER'S REPORT TO THE TRUSTEES OF THE INTERNATIONAL CML FOUNDATION (REGISTERED NUMBER: 06996068)
Independent examiner's report to the trustees of The International CML Foundation ('the Company')
I report to the charity trustees on my examination of the accounts of the Company for the year ended 31st August 2020.
Responsibilities and basis of report
As the charity's trustees of the Company (and also its directors for the purposes of company law) you are responsible for the preparation of the accounts in accordance with the requirements of the Companies Act 2006 ('the 2006 Act').
Having satisfied myself that the accounts of the Company are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of your charity's accounts as carried out under section 145 of the Charities Act 2011 ('the 2011 Act'). In carrying out my examination I have followed the Directions given by the Charity Commission under section 145(5) (b) of the 2011 Act.
Independent examiner's statement
I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe:
-
accounting records were not kept in respect of the Company as required by section 386 of the 2006 Act; or
-
the accounts do not accord with those records; or
-
the accounts do not comply with the accounting requirements of section 396 of the 2006 Act other than any requirement that the accounts give a true and fair view which is not a matter considered as part of an independent examination; or
-
the accounts have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities (applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)).
I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.
R Appleyard FCA ICAEW Gibbons Mannington & Phipps LLP Chartered Accountants 20 Eversley Road Bexhill-on-Sea East Sussex TN40 1HE
15th June 2021
Page 6
THE INTERNATIONAL CML FOUNDATION
STATEMENT OF FINANCIAL ACTIVITIES FOR THE YEAR ENDED 31ST AUGUST 2020
| Unrestricted funds Notes £ INCOME AND ENDOWMENTS FROM Donations and legacies 65,872 Other income 2 (21,893) Total 43,979 EXPENDITURE ON Charitable activities Preceptorships 532 Diagnosis & testing - Virtual Education Program 531 Scientific meetings 9,183 ICMLF Forum 30,370 Clinical forum - Communications 533 Fundraising 533 Cure C 533 Candid 35,998 Other 19,718 Total 97,931 NET INCOME/(EXPENDITURE) (53,952) RECONCILIATION OF FUNDS Total funds brought forward 281,986 TOTAL FUNDS CARRIED FORWARD 228,034 |
Restricted funds £ 156,392 - 156,392 36,160 1,035 30,067 4,960 - - 31,403 20,948 4,783 - - 129,356 27,036 127,734 154,770 |
2020 Total funds £ 222,264 (21,893) 200,371 36,692 1,035 30,598 14,143 30,370 - 31,936 21,481 5,316 35,998 19,718 227,287 (26,916) 409,720 382,804 |
2019 Total funds £ 376,919 1,387 |
|---|---|---|---|
| 378,306 99,253 19,347 52,117 17,000 44,946 2,192 29,719 34,184 6,355 - 18,781 |
|||
| 323,894 | |||
| 54,412 355,308 |
|||
| 409,720 |
The notes form part of these financial statements
Page 7
THE INTERNATIONAL CML FOUNDATION (REGISTERED NUMBER: 06996068)
BALANCE SHEET 31ST AUGUST 2020
| Unrestricted funds Notes £ CURRENT ASSETS Debtors 10 92,949 Cash at bank and in hand 139,255 232,204 CREDITORS Amounts falling due within one year 11 (4,171) NET CURRENT ASSETS 228,033 TOTAL ASSETS LESS CURRENT LIABILITIES 228,033 NET ASSETS 228,033 FUNDS 12 Unrestricted funds Restricted funds TOTAL FUNDS |
Restricted funds £ - 154,771 154,771 - 154,771 154,771 154,771 |
2020 Total funds £ 92,949 294,026 386,975 (4,171) 382,804 382,804 382,804 228,033 154,771 382,804 |
2019 Total funds £ 52,214 361,466 413,680 (3,960) 409,720 409,720 409,720 281,986 127,734 409,720 |
|---|---|---|---|
The charitable company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31st August 2020.
The members have not required the company to obtain an audit of its financial statements for the year ended 31st August 2020 in accordance with Section 476 of the Companies Act 2006.
The trustees acknowledge their responsibilities for
-
(a) ensuring that the charitable company keeps accounting records that comply with Sections 386 and 387 of the Companies Act 2006 and
-
(b) preparing financial statements which give a true and fair view of the state of affairs of the charitable company as at the end of each financial year and of its surplus or deficit for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the charitable company.
These financial statements have been prepared in accordance with the provisions applicable to charitable companies subject to the small companies regime.
The financial statements were approved by the Board of Trustees and authorised for issue on 9th June 2021 and were signed on its behalf by:
T P Hughes - Trustee
The notes form part of these financial statements
Page 8
NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST AUGUST 2020
THE INTERNATIONAL CML FOUNDATION
1. ACCOUNTING POLICIES
Basis of preparing the financial statements
The financial statements of the charitable company, which is a public benefit entity under FRS 102, have been prepared in accordance with the Charities SORP (FRS 102) 'Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019)', Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.
Income
Items of income are recognised and included in the accounts when all of the following criteria are met:
-
- The charity or its subsidiary have entitlement to the funds;
-
- any performance conditions attached to the item(s) of income have been met or are fully
-
within the control of the charity or its subsidiary;
-
- there is sufficient certainty that receipt of the income is considered probable; and
-
the amount can be measured reliably.
Expenditure
Liabilities are recognised as expenditure as soon as there is a legal or constructive obligation committing the charity to that expenditure, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all cost related to the category. Where costs cannot be directly attributed to particular headings they have been allocated to activities on a basis consistent with the use of resources.
Grants offered subject to conditions which have not been met at the year end date are noted as a commitment but not accrued as expenditure.
Debtors
Debtors are recognised at the settlement amount due after any trade discount offered. Prepayments are valued at the amount prepaid after taking account of any trade discounts due.
Creditors and provisions
Creditors and provisions are recognised where the charity has a present obligation resulting from a past event that will probably result in the transfer of funds to a third party and the amount due to settle the obligation can be measured or estimated reliably. Creditors and provisions are normally recognised at their settlement amount after allowing for any trade discounts due.
Taxation
The charity is exempt from corporation tax on its charitable activities.
Fund accounting
Unrestricted funds can be used in accordance with the charitable objectives at the discretion of the trustees.
Restricted funds can only be used for particular restricted purposes within the objects of the charity. Restrictions arise when specified by the donor or when funds are raised for particular restricted purposes.
Further explanation of the nature and purpose of each fund is included in the notes to the financial statements.
continued...
Page 9
NOTES TO THE FINANCIAL STATEMENTS - continued FOR THE YEAR ENDED 31ST AUGUST 2020
THE INTERNATIONAL CML FOUNDATION
1. ACCOUNTING POLICIES - continued
Foreign currencies
Assets and liabilities in foreign currencies are translated into sterling at the rates of exchange ruling at the balance sheet date. Transactions in foreign currencies are translated into sterling at the rate of exchange ruling at the date of transaction. Exchange differences are taken into account in arriving at the operating result and are shown as other income.
2. OTHER INCOME
Other income consists of the profit on foreign currency exchange in accordance with the accounting policy on foreign exchange transactions.
3. GRANTS PAYABLE
| GRANTS PAYABLE | ||
|---|---|---|
| Preceptorships Diagnosis & testing |
2020 £ 23,963 1,035 24,998 |
2019 £ 76,623 9,457 |
| 86,080 |
4. SUPPORT COSTS
| Management fees £ Other resources expended 16,252 Preceptorships 12,197 Virtual Education Program 28,198 Scientific meetings 3,611 ICMLF Forum 5,690 Communications 22,523 Fundraising 9,029 Cure C 4,514 Candid 35,398 137,412 |
Finance £ 1,536 - - - - - - - - 1,536 |
Other £ 1,930 - - - - - - - - 1,930 |
Governance costs £ - 532 532 532 532 533 533 533 533 4,260 |
Totals £ 19,718 12,729 28,730 4,143 6,222 23,056 9,562 5,047 35,931 |
|---|---|---|---|---|
| 145,138 |
continued...
Page 10
THE INTERNATIONAL CML FOUNDATION
NOTES TO THE FINANCIAL STATEMENTS - continued FOR THE YEAR ENDED 31ST AUGUST 2020
4. SUPPORT COSTS - continued
Support costs, included in the above, are as follows:
Management fees
| Management & admin Management & admin Management & admin Finance Bank charges Other Sundry office costs Governance costs Preceptorships £ Accountancy - Independent examination fee 532 |
Scientific meetings £ 3,611 Cure C £ 4,514 Virtual Education Program £ 532 |
Other Virtual resources Education expended Preceptorships Program £ £ £ 16,252 12,197 28,198 ICMLF Forum Communications Fundraising £ £ £ 5,690 22,523 9,029 2020 2019 Total Total Candid activities activities £ £ £ 35,398 137,412 125,954 2020 2019 Other resources Total expended activities £ £ 1,536 1,841 2020 2019 Other resources Total expended activities £ £ 1,930 1,809 Scientific ICMLF meetings Forum Communications £ £ £ 532 532 533 |
|---|---|---|
continued...
Page 11
THE INTERNATIONAL CML FOUNDATION
NOTES TO THE FINANCIAL STATEMENTS - continued FOR THE YEAR ENDED 31ST AUGUST 2020
4. SUPPORT COSTS - continued
Governance costs - continued
| 2020 | 2019 | ||||
|---|---|---|---|---|---|
| Total | Total | ||||
| Fundraising | Cure C | Candid | activities | activities | |
| £ | £ | £ | £ | £ | |
| Accountancy - | |||||
| Independent | |||||
| examination fee | 533 | 533 | 533 | 4,260 | 4,320 |
| NET INCOME/(EXPENDITURE) | |||||
| Net income/(expenditure) is stated after charging/(crediting): | |||||
| 2020 | 2019 | ||||
| £ | £ | ||||
| Accountancy - Independent examination fee | 4,260 | 4,320 |
5. NET INCOME/(EXPENDITURE)
6. TRUSTEES' REMUNERATION AND BENEFITS
There were no trustees' remuneration or other benefits for the year ended 31st August 2020 nor for the year ended 31st August 2019.
Trustees' expenses
There were no trustees' expenses paid for the year ended 31st August 2020 nor for the year ended 31st August 2019.
7. STAFF COSTS
The average monthly number of employees during the year was as follows:
| 2020 | 2019 | 2019 | |||||
|---|---|---|---|---|---|---|---|
| Charitable activities | 3 | 3 | |||||
| The number of employees |
whose | employee | benefits | (excluding | employer | pension | costs) |
| exceeded £60,000 was: | |||||||
| 2020 | 2019 | ||||||
| £80,001 - £90,000 | - | 1 | |||||
| £90,001 - £100,000 | 1 | - | |||||
| 1 | 1 |
continued...
Page 12
THE INTERNATIONAL CML FOUNDATION
NOTES TO THE FINANCIAL STATEMENTS - continued FOR THE YEAR ENDED 31ST AUGUST 2020
| 8. COMPARATIVES FOR THE STATEMENT OF FINANCIAL ACTIVITIES Unrestricted funds £ INCOME AND ENDOWMENTS FROM Donations and legacies 144,635 Other income 1,387 Total 146,022 EXPENDITURE ON Charitable activities Preceptorships 99,253 Diagnosis & testing 480 Virtual Education Program 6,464 Scientific meetings 17,000 ICMLF Forum 34,155 Clinical forum 2,192 Communications 480 Fundraising 34,184 Cure C 6,355 Other 18,781 Total 219,344 NET INCOME/(EXPENDITURE) (73,322) RECONCILIATION OF FUNDS Total funds brought forward 355,308 TOTAL FUNDS CARRIED FORWARD 281,986 |
Restricted funds £ 232,284 - 232,284 - 18,867 45,653 - 10,791 - 29,239 - - - 104,550 127,734 - 127,734 |
Total funds £ 376,919 1,387 |
|---|---|---|
| 378,306 99,253 19,347 52,117 17,000 44,946 2,192 29,719 34,184 6,355 18,781 |
||
| 323,894 | ||
| 54,412 355,308 |
||
| 409,720 |
9. VOLUNTEERS
The charity heavily relies upon the many medical professionals who donate their time to help run the various charitable activities undertaken. It is not possible to accurately calculate the value of the services contributed by these volunteers and therefore the numbers do not reflect either the income or expenditure, however it is thought to be in the region of £230,000.
continued...
Page 13
THE INTERNATIONAL CML FOUNDATION
NOTES TO THE FINANCIAL STATEMENTS - continued FOR THE YEAR ENDED 31ST AUGUST 2020
10. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
| DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR | |
|---|---|
| 2020 | 2019 |
| £ | £ |
| Other debtors 92,949 |
52,214 |
| Included within other debtors is a balance of £84,202 in respect of funds held by Paypal. As a | |
| result of a change of personnel, the account access is being transferred by Paypal, and until this | |
| process has been completed the charity cannot transfer or use these funds. |
| 11. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR Accrued expenses 12. MOVEMENT IN FUNDS At 1/9/19 £ Unrestricted funds General fund 281,986 Cepheid - 281,986 Restricted funds Bristol-Myers Squibb 680 Novartis Pharmaceuticals Corporation 124,445 Takeda Oncology 2,609 Pfizer - Novartis Killi Climb - 127,734 TOTAL FUNDS 409,720 |
2020 £ 4,171 Net movement in funds £ (57,868) 3,915 (53,953) (680) (1,035) (2,609) 23,118 8,243 27,037 (26,916) |
2019 £ 3,960 At 31/8/20 £ 224,118 3,915 |
2019 £ 3,960 |
|---|---|---|---|
| 228,033 - 123,410 - 23,118 8,243 |
|||
| 154,771 | |||
| 382,804 |
continued...
Page 14
THE INTERNATIONAL CML FOUNDATION
NOTES TO THE FINANCIAL STATEMENTS - continued FOR THE YEAR ENDED 31ST AUGUST 2020
12. MOVEMENT IN FUNDS - continued
Net movement in funds, included in the above are as follows:
| Unrestricted funds General fund Cepheid Restricted funds Bristol-Myers Squibb Novartis Pharmaceuticals Corporation Takeda Oncology Pfizer Novartis Killi Climb Novartis Colt Bristol-Myers Squibb TOTAL FUNDS Comparatives for movement in funds Unrestricted funds General fund Restricted funds Bristol-Myers Squibb Novartis Pharmaceuticals Corporation Takeda Oncology TOTAL FUNDS |
Incoming resources £ 40,064 3,915 43,979 - - - 117,458 26,144 4,960 7,830 156,392 200,371 At 1/9/18 £ 355,308 - - - - 355,308 |
Resources expended £ (97,932) - (97,932) (680) (1,035) (2,609) (94,340) (17,901) (4,960) (7,830) (129,355) (227,287) Net movement in funds £ (73,322) 680 124,445 2,609 127,734 54,412 |
Movement in funds £ (57,868) 3,915 (53,953) (680) (1,035) (2,609) 23,118 8,243 - - 27,037 (26,916) At 31/8/19 £ 281,986 680 124,445 2,609 127,734 409,720 |
||
|---|---|---|---|---|---|
continued...
Page 15
NOTES TO THE FINANCIAL STATEMENTS - continued FOR THE YEAR ENDED 31ST AUGUST 2020
THE INTERNATIONAL CML FOUNDATION
12. MOVEMENT IN FUNDS - continued
Comparative net movement in funds, included in the above are as follows:
| Incoming | Resources | Movement | |
|---|---|---|---|
| resources | expended | in funds | |
| £ | £ | £ | |
| Unrestricted funds | |||
| General fund | 146,022 | (219,344) | (73,322) |
| Restricted funds | |||
| Incyte | 31,847 | (31,847) | - |
| Bristol-Myers Squibb | 25,277 | (24,597) | 680 |
| Novartis Pharmaceuticals | |||
| Corporation | 143,312 | (18,867) | 124,445 |
| Takeda Oncology | 31,848 | (29,239) | 2,609 |
| 232,284 | (104,550) | 127,734 | |
| TOTAL FUNDS | 378,306 | (323,894) | 54,412 |
A current year 12 months and prior year 12 months combined position is as follows:
| Unrestricted funds General fund Cepheid Restricted funds Novartis Pharmaceuticals Corporation Pfizer Novartis Killi Climb TOTAL FUNDS |
At 1/9/18 £ 355,308 - 355,308 - - - - 355,308 |
Net movement in funds £ (131,190) 3,915 (127,275) 123,410 23,118 8,243 154,771 27,496 |
At 31/8/20 £ 224,118 3,915 |
|---|---|---|---|
| 228,033 123,410 23,118 8,243 |
|||
| 154,771 | |||
| 382,804 |
continued...
Page 16
THE INTERNATIONAL CML FOUNDATION
NOTES TO THE FINANCIAL STATEMENTS - continued FOR THE YEAR ENDED 31ST AUGUST 2020
12. MOVEMENT IN FUNDS - continued
A current year 12 months and prior year 12 months combined net movement in funds, included in the above are as follows:
| Unrestricted funds General fund Cepheid Restricted funds Incyte Bristol-Myers Squibb Novartis Pharmaceuticals Corporation Takeda Oncology Pfizer Novartis Killi Climb Novartis Colt Bristol-Myers Squibb TOTAL FUNDS |
Incoming resources £ 186,086 3,915 190,001 31,847 25,277 143,312 31,848 117,458 26,144 4,960 7,830 388,676 578,677 |
Resources expended £ (317,276) - (317,276) (31,847) (25,277) (19,902) (31,848) (94,340) (17,901) (4,960) (7,830) (233,905) (551,181) |
Movement in funds £ (131,190) 3,915 (127,275) - - 123,410 - 23,118 8,243 - - 154,771 27,496 |
|---|---|---|---|
13. RELATED PARTY DISCLOSURES
There were no related party transactions for the year ended 31st August 2020.
Page 17